Masanobu Kawai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9319801/publications.pdf

Version: 2024-02-01

		186265	206112
73	2,474	28	48
papers	citations	h-index	g-index

74	74	74	3783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Disruption of the circadian rhythms and its relationship with pediatric obesity. Pediatrics International, 2022, 64, .	0.5	14
2	Beta-human chorionic gonadotropin-producing neuroblastoma: an unrecognized cause of gonadotropin-independent precocious puberty. Endocrine Journal, 2022, 69, 313-318.	1.6	2
3	Circulating insulinâ€like growth factor 1 levels are reduced in very young children with Praderâ€“Willi syndrome independent of anthropometric parameters and nutritional status. Clinical Endocrinology, 2022, 96, 346-352.	2.4	3
4	Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Praderâ€“Willi syndrome independent of lean mass. Journal of Pediatric Endocrinology and Metabolism, 2022, .	0.9	1
5	Growth-related skeletal changes and alterations in phosphate metabolism. Bone, 2022, 161, 116430.	2.9	5
6	Histological analysis of testes in patients with 5 alpha-reductase deficiency type 2: comparison with cryptorchid testes in patients without endocrinological abnormalities and a review of the literature. Clinical Pediatric Endocrinology, 2022, , .	0.8	0
7	Growth hormone treatment for extremely low birthweight children born small for gestational age. Pediatrics International, 2021, 63, 46-52.	0.5	0
8	Ultrasonography for inguinal hernia led to the diagnosis of complete androgen insensitivity syndrome. Pediatrics International, 2021, 63, 122-123.	0.5	0
9	Renal function in shortâ€statured children born small for gestational age and treated with growth hormone. Pediatrics International, 2021, 63, 775-781.	0.5	1
10	Central hypothyroidism improves with age in very young children with Praderâ€Willi syndrome. Clinical Endocrinology, 2021, 94, 384-391.	2.4	10
11	Nephrogenic diabetes insipidus caused by a novel missense variant (p.S127Y) in the AVPR2 gene. Clinical Pediatric Endocrinology, 2021, 30, 115-118.	0.8	0
12	Acquired uniparental disomy of chromosome 7 in a patient with MIRAGE syndrome that veiled a pathogenic <i>SAMD9</i> variant. Clinical Pediatric Endocrinology, 2021, 30, 163-169.	0.8	1
13	Constitutional mismatch repair deficiency in childhood colorectal cancer harboring a de novo variant in the MSH6 gene: a case report. BMC Gastroenterology, 2021, 21, 60.	2.0	3
14	Male assignment in 5Î±â€reductase type 2 deficiency with female external genitalia. Pediatrics International, 2021, 63, 592-594.	0.5	3
15	Starting age of oestrogenâ€progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index. Clinical Endocrinology, 2021, 95, 84-91.	2.4	9
16	Diagnostic Pitfall: Mosaic Turner syndrome with a 46, XY lymphocyte karyotype. Pediatrics International, 2021, 63, 1122-1123.	0.5	0
17	Clonal osteoblastic cell lines with CRISPR/Cas9-mediated ablation of Pit1 or Pit2 show enhanced mineralization despite reduced osteogenic gene expression. Bone, 2021, 151, 116036.	2.9	4
18	Bone and fat. , 2021, , 833-846.		0

#	Article	IF	Citations
19	Hypophosphatasia in Japan: ALPL Mutation Analysis in 98 Unrelated Patients. Calcified Tissue International, 2020, 106, 221-231.	3.1	24
20	Lack of PTEN in osteocytes increases circulating phosphate concentrations by decreasing intact fibroblast growth factor 23 levels. Scientific Reports, 2020, 10, 21501.	3.3	5
21	Fat distribution in shortâ€stature children born small for gestational age. Pediatrics International, 2020, 62, 1351-1356.	0.5	3
22	MIRAGE syndrome caused by a novel missense variant (p.Ala1479Ser) in the SAMD9 gene. Human Genome Variation, 2020, 7, 4.	0.7	9
23	Visceral adipose tissue resides within the reference range in children with Prader-Willi syndrome receiving nutritional intervention on a regular basis. Endocrine Journal, 2020, 67, 1029-1037.	1.6	2
24	Policy statement of enteral nutrition for preterm and very low birthweight infants. Pediatrics International, 2020, 62, 124-127.	0.5	17
25	Ultra-low-dose estrogen therapy for female hypogonadism. Clinical Pediatric Endocrinology, 2020, 29, 49-53.	0.8	4
26	A nationwide questionnaire survey targeting Japanese pediatric endocrinologists regarding transitional care in childhood, adolescent, and young adult cancer survivors. Clinical Pediatric Endocrinology, 2020, 29, 55-62.	0.8	10
27	A retrospective multicenter study of bone mineral density in adolescents and adults with Turner syndrome in Japan. Endocrine Journal, 2020, 67, 1023-1028.	1.6	9
28	Genotype-phenotype correlation analysis in Japanese patients with Noonan syndrome. Endocrine Journal, 2019, 66, 983-994.	1.6	12
29	CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia. Hepatology Research, 2019, 49, 314-323.	3.4	13
30	CREB activation in hypertrophic chondrocytes is involved in the skeletal overgrowth in epiphyseal chondrodysplasia Miura type caused by activating mutations of natriuretic peptide receptor B. Human Molecular Genetics, 2019, 28, 1183-1198.	2.9	8
31	Intestinal clock system regulates skeletal homeostasis. JCI Insight, 2019, 4, .	5.0	23
32	For Debate: When is Selenium Deficiency Suspected and When is Its Measurement Indicated?. Pediatric Endocrinology Reviews, 2019, 16, 307-310.	1.2	0
33	Thyroid hormone status in patients with severe selenium deficiency. Clinical Pediatric Endocrinology, 2018, 27, 67-74.	0.8	15
34	Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome. Endocrine Journal, 2018, 65, 1127-1137.	1.6	11
35	Phosphate as a Signaling Molecule and Its Sensing Mechanism. Physiological Reviews, 2018, 98, 2317-2348.	28.8	112
36	Extracellular Phosphate Induces the Expression of Dentin Matrix Protein 1 Through the FGF Receptor in Osteoblasts. Journal of Cellular Biochemistry, 2017, 118, 1151-1163.	2.6	40

#	Article	IF	Citations
37	Inorganic Phosphate Activates the AKT/mTORC1 Pathway and Shortens the Life Span of an Î±â€Klothoâ€“Deficient Model. Journal of the American Society of Nephrology: JASN, 2016, 27, 2810-2824.	6.1	38
38	The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis. Hormone Molecular Biology and Clinical Investigation, 2016, 28, 55-67.	0.7	26
39	Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation. Journal of Bone and Mineral Metabolism, 2015, 33, 342-354.	2.7	32
40	Dysregulated Gene Expression in the Primary Osteoblasts and Osteocytes Isolated from Hypophosphatemic Hyp Mice. PLoS ONE, 2014, 9, e93840.	2.5	48
41	Elevated Fibroblast Growth Factor 23 Exerts Its Effects on Placenta and Regulates Vitamin D Metabolism in Pregnancy of Hyp Mice. Journal of Bone and Mineral Research, 2014, 29, 1627-1638.	2.8	45
42	Sympathetic Activation Induces Skeletal Fgf23 Expression in a Circadian Rhythm-dependent Manner. Journal of Biological Chemistry, 2014, 289, 1457-1466.	3.4	63
43	Bone and Fat. , 2013, , 963-976.		0
44	Bone Marrow Fat and Bone Mass. , 2013, , 167-179.		1
45	FGF23 Suppresses Chondrocyte Proliferation in the Presence of Soluble Î±-Klotho both in Vitro and in Vivo. Journal of Biological Chemistry, 2013, 288, 2414-2427.	3.4	51
46	Adipose tissue and bone: role of PPARÎ³ in adipogenesis and osteogenesis. Hormone Molecular Biology and Clinical Investigation, 2013, 15, 105-113.	0.7	15
47	Sodiumâ€coupled neutral amino acid transporter 4 functions as a regulator of protein synthesis during liver development. Hepatology Research, 2013, 43, 1211-1223.	3.4	12
48	Altered thermogenesis and impaired bone remodeling in Misty mice. Journal of Bone and Mineral Research, 2013, 28, 1885-1897.	2.8	57
49	Vinculin Functions as Regulator of Chondrogenesis. Journal of Biological Chemistry, 2012, 287, 15760-15775.	3.4	34
50	A High-Fat Diet Induces Bone Loss in Mice Lacking the Alox5 Gene. Endocrinology, 2012, 153, 6-16.	2.8	20
51	The Insulin-Like Growth Factor System in Bone. Endocrinology and Metabolism Clinics of North America, 2012, 41, 323-333.	3.2	84
52	Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. Journal of Bone and Mineral Research, 2012, 27, 390-400.	2.8	38
53	Emerging therapeutic opportunities for skeletal restoration. Nature Reviews Drug Discovery, 2011, 10, 141-156.	46.4	125
54	An essential role for the circadianâ€regulated gene Nocturnin in osteogenesis: the importance of local timekeeping in skeletal homeostasis. Annals of the New York Academy of Sciences, 2011, 1237, 58-63.	3.8	37

#	Article	IF	Citations
55	The Heparin-binding Domain of IGFBP-2 Has Insulin-like Growth Factor Binding-independent Biologic Activity in the Growing Skeleton. Journal of Biological Chemistry, 2011, 286, 14670-14680.	3.4	53
56	The IGFâ€‹ regulatory system and its impact on skeletal and energy homeostasis. Journal of Cellular Biochemistry, 2010, 111, 14-19.	2.6	54
57	Nocturnin: a circadian target of Ppargâ€‹induced adipogenesis. Annals of the New York Academy of Sciences, 2010, 1192, 131-138.	3.8	25
58	A circadian-regulated gene, Nocturnin , promotes adipogenesis by stimulating PPAR-Î³ nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10508-10513.	7.1	136
59	The many facets of PPARÎ³: novel insights for the skeleton. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E3-E9.	3.5	56
60	Skeletal aging and the adipocyte program. Cell Cycle, 2010, 9, 3672-3678.	2.6	50
61	A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis. Journal of Endocrinology, 2010, 204, 241-253.	2.6	29
62	Adiposity and bone accrualâ€”still an established paradigm?. Nature Reviews Endocrinology, 2010, 6, 63-64.	9.6	22
63	Minireview: A Skeleton in Serotoninâ€™s Closet?. Endocrinology, 2010, 151, 4103-4108.	2.8	28
64	Nocturnin Suppresses Igf1 Expression in Bone by Targeting the 3â€² Untranslated Region of Igf1 mRNA. Endocrinology, 2010, 151, 4861-4870.	2.8	44
65	PPARÎ³: a circadian transcription factor in adipogenesis and osteogenesis. Nature Reviews Endocrinology, 2010, 6, 629-636.	9.6	277
66	Fat targets for skeletal health. Nature Reviews Rheumatology, 2009, 5, 365-372.	8.0	124
67	Insulin-like growth factor-I and bone: lessons from mice and men. Pediatric Nephrology, 2009, 24, 1277-1285.	1.7	49
68	Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARÎ³ pathway. Journal of Molecular Endocrinology, 2007, 38, 19-34.	2.5	84
69	Wnt/Lrp/Î²-catenin signaling suppresses adipogenesis by inhibiting mutual activation of PPARÎ³ and C/EBPÎ±. Biochemical and Biophysical Research Communications, 2007, 363, 276-282.	2.1	98
70	Novel mutation of gene coding for glial fibrillary acidic protein in a Japanese patient with Alexander disease. Brain and Development, 2006, 28, 60-62.	1.1	6
71	Cowâ€™s milk allergy presenting Hirschsprungâ€™s disease-mimicking symptoms. Pediatric Surgery International, 2005, 21, 850-852.	1.4	23
72	Skeletal defects inringelschwanzmutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development (Cambridge), 2004, 131, 5469-5480.	2.5	158

#	Article	IF	Citations
73	Effect of Baclofen on Emesis and 24-Hour Esophageal pH in Neurologically Impaired Children With Gastroesophageal Reflux Disease. Journal of Pediatric Gastroenterology and Nutrition, 2004, 38, 317-323.	1.8	59